A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression

Molecular Cancer Therapeutics

Volumn 10, Issue 5, 2011, Pages 850-860

  Van Zijl, Franziska ^a   Mall, Sabine ^a   Machat, Georg ^a   Pirker, Christine ^a   Zeillinger, Robert ^b   Weinhaeusel, Andreas ^c   Bilban, Martin ^c   Berger, Walter ^a   Mikulits, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ERLOTINIB; SORAFENIB;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; DRUG EFFICACY; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IC 50; LIVER CELL; LIVER CELL CARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; MALE; MESODERM; MICROSATELLITE REPEATS; MIDDLE AGED; OSTEONECTIN; PHENOTYPE;

EID: 79956007927     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0917     Document Type: Article

References (26)

1. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
2. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-29. (Pubitemid 351757205)
3. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548-58. (Pubitemid 41267170)
4. Giannelli G. The epithelial-mesenchymal transition: fact or fiction in cancer? Hepatology 2009;50:1344-6.
5. van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 2009;5:1169-79.
6. Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009;50:1464-74.
7. Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimosato Y. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1990;66:2174-9.
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
9. Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther 2008;25:1089-104.
10. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009;373:614-6.
11. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20-37.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. (Pubitemid 43112690)
13. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42. (Pubitemid 36152543)
14. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006;32:594-606. (Pubitemid 44645026)
15. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
16. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 2010;16: 390-7.
17. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
18. van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009;28:4022-33.
19. Weinhaeusel A, Thiele S, Hofner M, Hiort O, Noehammer C. PCR-based analysis of differentially methylated regions of GNAS enables convenient diagnostic testing of pseudohypoparathyroidism type Ib. Clin Chem 2008;54:1537-45.
20. Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, et al. New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. Br J Cancer 2008;99:151-9. (Pubitemid 351920238)
21. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998;1378: F79-113.
22. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008;47:2059-67. (Pubitemid 351945572)
23. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40.
24. Atorrasagasti C, Malvicini M, Aquino JB, Alaniz L, Garcia M, Bolontrade M, et al. Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells. Int J Cancer 2010;126:2726-40.
25. Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, Carles J, et al. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 1999;189:46-52. (Pubitemid 29406818)
26. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 2010;30:75-86.